company background image
BHVN

Biohaven Pharmaceutical HoldingNYSE:BHVN Stock Report

Market Cap

US$7.5b

7D

0.09%

1Y

24.6%

Updated

26 Nov, 2021

Data

Company Financials +
BHVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

BHVN Stock Overview

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Biohaven Pharmaceutical Holding
Historical stock prices
Current Share PriceUS$113.85
52 Week HighUS$151.51
52 Week LowUS$62.57
Beta0.95
1 Month Change-16.96%
3 Month Change-12.54%
1 Year Change24.62%
3 Year Change234.95%
5 Year Changen/a
Change since IPO550.57%

Recent News & Updates

Shareholder Returns

BHVNUS BiotechsUS Market
7D0.09%0.4%-2.7%
1Y24.6%5.3%21.3%

Return vs Industry: BHVN exceeded the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: BHVN exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is BHVN's price volatile compared to industry and market?
BHVN volatility
BHVN Average Weekly Movement6.3%
Biotechs Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: BHVN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BHVN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013825Vlad Corichttps://www.biohavenpharma.com

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis.

Biohaven Pharmaceutical Holding Fundamentals Summary

How do Biohaven Pharmaceutical Holding's earnings and revenue compare to its market cap?
BHVN fundamental statistics
Market CapUS$7.46b
Earnings (TTM)-US$865.14m
Revenue (TTM)US$307.61m

24.2x

P/S Ratio

-8.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BHVN income statement (TTM)
RevenueUS$307.61m
Cost of RevenueUS$65.68m
Gross ProfitUS$241.93m
ExpensesUS$1.11b
Earnings-US$865.14m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-13.21
Gross Margin78.65%
Net Profit Margin-281.25%
Debt/Equity Ratio-155.5%

How did BHVN perform over the long term?

See historical performance and comparison

Valuation

Is Biohaven Pharmaceutical Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BHVN ($113.85) is trading below our estimate of fair value ($688.46)

Significantly Below Fair Value: BHVN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BHVN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BHVN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BHVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BHVN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Biohaven Pharmaceutical Holding forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

73.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BHVN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: BHVN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BHVN's is expected to become profitable in the next 3 years.

Revenue vs Market: BHVN's revenue (41.6% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: BHVN's revenue (41.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BHVN is forecast to be unprofitable in 3 years.


Past Performance

How has Biohaven Pharmaceutical Holding performed over the past 5 years?

-46.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BHVN is currently unprofitable.

Growing Profit Margin: BHVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BHVN is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.

Accelerating Growth: Unable to compare BHVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BHVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: BHVN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Biohaven Pharmaceutical Holding's financial position?


Financial Position Analysis

Short Term Liabilities: BHVN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BHVN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BHVN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BHVN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BHVN has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if BHVN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Biohaven Pharmaceutical Holding current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BHVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BHVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BHVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BHVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BHVN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Vlad Coric (50 yo)

6.08yrs

Tenure

US$1,259,152

Compensation

Dr. Vladimir Coric, also known as Vlad, M.D., is Director at Pyramid Biosciences Inc. since August 2020. He has been Independent Director of Social Capital Suvretta Holdings Corp. I since June 29, 2021. He...


CEO Compensation Analysis

Compensation vs Market: Vlad's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD6.24M).

Compensation vs Earnings: Vlad's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BHVN's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: BHVN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BHVN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.3%.


Top Shareholders

Company Information

Biohaven Pharmaceutical Holding Company Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Biohaven Pharmaceutical Holding Company Ltd.
  • Ticker: BHVN
  • Exchange: NYSE
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.457b
  • Shares outstanding: 65.50m
  • Website: https://www.biohavenpharma.com

Number of Employees


Location

  • Biohaven Pharmaceutical Holding Company Ltd.
  • 215 Church Street
  • New Haven
  • Connecticut
  • 6510
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:03
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.